Skip to Content

Illumina Inc ILMN

Morningstar Rating
$114.49 −1.30 (1.12%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Illumina: Completes Spinoff of Grail to Shareholders

Illumina has completed its planned spin off of Grail directly to shareholders, with trading starting on June 25. As highlighted when this announcement was made in early June, we have reduced our fair value estimate on Illumina to $188 per share, which includes $180 of value on the firm's core sequencing business plus about $8 of value on Illumina’s remaining 14.5% stake in Grail, down from a total valuation of $228 previously. With this divestiture, Illumina is now focused on its narrow-moat sequencing business, which has intangible asset and switching cost moat sources.

Price vs Fair Value

ILMN is trading at a 777% premium.
Price
$114.49
Fair Value
$619.00
Uncertainty
High
1-Star Price
$183.50
5-Star Price
$627.20
Economic Moat
Qylskz
Capital Allocation
Mwzybxmc

Bulls Say, Bears Say

Bulls

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth opportunities for Illumina with or without Grail.

Bears

Disruptive technology risks could threaten Illumina's industry-leading sequencing platform, leading to market share losses and profit declines.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ILMN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$115.79
Day Range
$113.32116.21
52-Week Range
$86.50190.15
Bid/Ask
$113.20 / $121.50
Market Cap
$18.24 Bil
Volume/Avg
1.4 Mil / 2.7 Mil

Key Statistics

Price/Earnings (Normalized)
130.10
Price/Sales
4.03
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
9,300

Competitors

Valuation

Metric
ILMN
TMO
GH
Price/Earnings (Normalized)
130.1024.72
Price/Book Value
3.174.4854.84
Price/Sales
4.034.875.95
Price/Cash Flow
38.8823.84
Price/Earnings
ILMN
TMO
GH

Financial Strength

Metric
ILMN
TMO
GH
Quick Ratio
1.181.195.52
Current Ratio
1.751.705.95
Interest Coverage
−15.224.83−195.67
Quick Ratio
ILMN
TMO
GH

Profitability

Metric
ILMN
TMO
GH
Return on Assets (Normalized)
1.28%8.69%−17.37%
Return on Equity (Normalized)
2.25%18.71%−213.40%
Return on Invested Capital (Normalized)
1.78%10.97%−22.39%
Return on Assets
ILMN
TMO
GH
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
MrnhmnmnRcm$204.0 Bil
Danaher Corp
DHR
PqhqfqrvdLrlxd$180.4 Bil
IQVIA Holdings Inc
IQV
PlglzcxpKbmddw$40.9 Bil
IDEXX Laboratories Inc
IDXX
WxzbgrzsbCrmycbk$38.7 Bil
Agilent Technologies Inc
A
BtqzvfztgSgqdk$38.4 Bil
Mettler-Toledo International Inc
MTD
GmlpvlcdhNxdmndx$28.7 Bil
Icon PLC
ICLR
XdywlsnHycpnk$27.3 Bil
Waters Corp
WAT
WcszcqrmHcvs$18.0 Bil
Labcorp Holdings Inc
LH
KckjlsvhmHrzlpj$17.8 Bil

Sponsor Center